The primary outcome results for the SPS@ trial suggested that a lower systolic target blood pressure ( < @ mm Hg ) might be beneficial for reducing the risk of recurrent stroke compared with a higher target ( @-@ mm Hg ) , but that the addition of clopidogrel to aspirin was not beneficial compared with aspirin plus placebo .